Clinical factors related to morbidity and mortality in high‐risk heart failure patients: the GUIDE‐IT predictive model and risk score. (27th March 2019)

• Record Type: Journal Article
• Authors: O'Connor, Christopher; Fiuzat, Mona; Mulder, Hillary; Coles, Adrian; Ahmad, Tariq; Ezekowitz, Justin A.; Adams, Kirkwood F.; Piña, Ileana L.; Anstrom, Kevin J.; Cooper, Lawton S.; Mark, Daniel B.; Whellan, David J.; Januzzi, James L.; Leifer, Eric S.; Felker, G. Michael
• Is Part Of: European journal of heart failure. Volume 21:Number 6(2019)
• Page Start: 770
• Page End: 778
• Publication Date: 2019-03-27
• Subjects: Risk stratification -- Systolic heart failure -- Predictive risk model -- Natriuretic peptides; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.1450
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract : Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short‐ and long‐term follow‐up period. We undertook the current analysis of participants in the GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. Methods and results: The GUIDE‐IT study randomized 894 high‐risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker‐guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all‐cause mortality, and the exploratory endpoint of 90‐day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow‐up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan–Meier event rate 34.5% at 12 months). Frequency of all‐cause deaths was 143 out of 894 patients (Kaplan–Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co‐morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score. Conclusion: Risk models using readily available clinical information are able to accurately predict short‐ and long‐term CV events and may be useful in optimizing care and enriching patients for clinical trials. Clinical trial registration: ClinicalTrials.gov ID number NCT01685840.